Acceptable references to establish first/second/third line treatment
-
In a disease state that does not have authoritative Canadian consensus guidelines, could a CDA (previously CADTH) Provisional Funding Algorithm be used to support which products are recommended to be used first-line, second-line, third-line, etc. Providing this as an example: https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf.
-
In a disease state that does not have authoritative Canadian consensus guidelines, could a CDA (previously CADTH) Provisional Funding Algorithm be used to support which products are recommended to be used first-line, second-line, third-line, etc. Providing this as an example: https://www.cda-amc.ca/sites/default/files/DRR/2024/PH0047_Multiple_Myeloma.pdf.
Good Morning, @maryssa
Historically, as confirmed by the provided document (see Background, paragraph 2 copy “Note that provisional funding algorithms are not treatment algorithms; they are neither meant to detail the full clinical management…”), these documents are not intended to be treatment algorithms. However, Canada's Drug Agency (CDA-AMC) has an expanded mandate and role, including improving medication prescribing practices. We will reach out to CDA to discuss whether their new mandate impacts PAAB review. Stay tuned.
-
Thanks Jennifer!
In the absence of authoritative Canadian consensus guidelines, is there another reference type you can recommend to support which products are recommended to be used first-line, second-line, third-line, etc?
